Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Azithromycin,Lopinavir,Ritonavir

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 14, 2020

            Details:

            A preliminary analysis shows no significant difference in the primary endpoint of 28-day mortality (19% azithromycin vs. 19% usual care) There was also no evidence of beneficial effects on the risk of progression to mechanical ventilation or length of hospital stay.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Colchicine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 27, 2020

            Details:

            Randomised Evaluation of COVid-19 Therapy (RECOVERY) trial will investigate colchicine, a commonly used anti-inflammatory treatment.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AB201

            Therapeutic Area: Infections and Infectious Diseases Product Name: rNAPc2

            Highest Development Status: Phase II/ Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 23, 2020

            Details:

            AB201 is the only novel compound being developed for COVID Associated Coagulopathy. The Company intends to initiate a Phase 2b clinical trial (ASPEN-COVID-19) of AB201 in approximately 100 patients hospitalized with COVID-19 in December 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ChAdOx1 nCoV-19

            Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222

            Highest Development Status: Phase II/ Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: National Institutes of Health

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 18, 2020

            Details:

            Results were published in the Lancet. The paper reported data on 560 people enrolled in the phase 2 portion of the phase 2/3 clinical trial of the ChAdOx1 nCoV-19 vaccine AstraZeneca is developing with the University of Oxford.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VIR-7831

            Therapeutic Area: Infections and Infectious Diseases Product Name: GSK4182136

            Highest Development Status: Phase II/ Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Vir Biotechnology

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 31, 2020

            Details:

            Phase 2/3 COMET-ICE study will investigate the safety and efficacy of antibody treatment in preventing hospitalization due to COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AZD1222

            Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222

            Highest Development Status: Phase II/ Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 20, 2020

            Details:

            COV001 is a blinded, multi-centre, randomised controlled Phase I/II trial assessing single dose of AZD1222 against a comparator meningococcal conjugate vaccine, MenACWY.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cabotegravir

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 07, 2020

            Details:

            Final data analysis from HPTN 083 study at AIDS 2020 shows investigational, long-acting injectable cabotegravir administered every two months is 66% more effective than daily pills in preventing HIV-1 acquisition.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lopinavir,Ritonavir

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 29, 2020

            Details:

            The trial Steering Committee concluded that there is no beneficial effect of lopinavir-ritonavir in patients hospitalised with COVID-19 and closed randomisation to that treatment arm.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AZD1222

            Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222

            Highest Development Status: Phase II/ Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: Brazilian Health Ministry

            Deal Size: $127.0 million Upfront Cash: Undisclosed

            Deal Type: Partnership June 28, 2020

            Details:

            The AstraZeneca drug candidate is considered as the leading vaccine in the world, and most advanced in terms of development to obtain license and be used as an official medication against the virus.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AZD1222

            Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222

            Highest Development Status: Phase II/ Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: AstraZeneca

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement June 22, 2020

            Details:

            Under the agreement, Symbiosis will provide AstraZeneca fast-track access to sterile vaccine drug product manufacturing capacity for clinical trial supply.